CD25 could be useful as a CML-LSC marker at diagnosis, and it has been shown that BCR/ABL1 TKIs downregulate STAT5- and CD25-expression in LSCs [38]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.